Recurrent Pneumonitis in Patients with Melanoma Treated with Immune Checkpoint Inhibitors

Keyphrases

• Melanoma 100%
• Immune Checkpoint Inhibitors 100%
• Recurrent Pneumonitis 100%
• Pneumonitis 80%
• Steroid Treatment 60%
• Rechallenge 60%
• Early Onset 40%
• First Episode 40%
• Treatment Discontinuation 40%
• Nivolumab 40%
• Immune-related Adverse Events 40%
• Immune-related Pneumonitis 40%
• Recurring 20%
• Nineteen 20%
• Monotherapy 20%
• Programmed Death-ligand 1 (PD-L1) 20%
• Metastatic Melanoma 20%
• Implications for Practice 20%
• Treatment Duration 20%
• Proper Management 20%
• Treatment Drugs 20%
• Complete Resolution 20%
• Close Monitoring 20%
• Melanoma Patients 20%
• Ipilimumab 20%
• Oncologic 20%
• Long-course 20%
• No Recurrence 20%
• Short Course 20%
• Advanced Melanoma 20%
• Anti-cytotoxic 20%
• IrAE 20%
• Drug Rechallenge 20%
• Anti-tumor Response 20%
• Cytotoxic T-lymphocyte antigen-4 (CTLA-4) 20%

Medicine and Dentistry

• Nodular Melanoma 100%
• Pneumonia 100%
• Immune Checkpoint Inhibitor 100%
• Steroid Treatment 27%
• Recurrent Disease 18%
• Immune-Related Adverse Events 18%
• Nivolumab 18%
• Immunotherapy 18%
• Programmed Cell Death 9%
• Metastatic Melanoma 9%
• Population Research 9%
• Treatment Duration 9%
• CTLA-4 9%
• Monotherapy 9%
• Ipilimumab 9%

Immunology and Microbiology

• Pneumonitis 100%
• Nivolumab 18%
• Immunotherapy 18%
• Population Research 9%
• Programmed Cell Death 1 9%
• CTLA-4 9%
• Ipilimumab 9%